Du Feng

Title: Du Feng: Innovator in Proteolysis-Targeting Chimeras

Introduction

Du Feng is a notable inventor based in Guangdong, China. He has made significant contributions to the field of proteolysis-targeting chimeras (PROTACs). His innovative work focuses on developing molecules that can effectively target and degrade specific proteins within cells.

Latest Patents

Du Feng holds a patent for a proteolysis-targeting chimera molecule and its preparation method and use. This patent describes a PROTAC molecule that includes a ligand for a target protein, specifically a pyridine carboxylic acid-1-oxide derivative. In experimental studies involving cells and zebrafish, this PROTAC molecule has demonstrated no toxic or side effects at concentrations that achieve the desired therapeutic effect. The molecule effectively inhibits human tyrosinase (TYR) at concentrations less than or equal to 1 μmol/L. Furthermore, it significantly reduces melanin production by degrading TYR, showcasing excellent solubility, safety, efficacy, and a low effective concentration.

Career Highlights

Throughout his career, Du Feng has worked with reputable institutions, including Guangzhou Medical University and Zhongshan Winstar Electrical Co., Ltd. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.

Collaborations

Du Feng has collaborated with notable colleagues such as Wei Yi and Yongquan Hu. Their combined efforts have further advanced the research and application of PROTAC technology.

Conclusion

Du Feng's contributions to the field of proteolysis-targeting chimeras highlight his innovative spirit and dedication to advancing medical science. His work not only demonstrates the potential of PROTACs in therapeutic applications but also sets a foundation for future research in this promising area.